ArticleClinical rheumatology2026
Evaluating the value of superoxide dismutase in anti-synthetase syndrome associated with interstitial lung disease.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo evaluate the clinical value of serum superoxide dismutase (SOD) in anti-synthetase syndrome-related interstitial lung disease (ASyS-ILD).
methodsWe conducted a retrospective study of 153 patients with anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD) at the Second Affiliated Hospital of Chongqing Medical University. Data collected included demographics, laboratory parameters [hemoglobin, absolute neutrophil count, absolute lymphocyte count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), creatine kinase (CK), lactate dehydrogenase (LDH), serum ferritin, serum superoxide dismutase (SOD), and myositis-specific antibodies], lung high-resolution computed tomography (HRCT) findings, treatment regimens, and recurrence. For comparison, serum SOD levels were also measured in 153 healthy individuals who served as the control group.
resultsCompared with the healthy control group, the serum SOD level in the ASyS-ILD group was significantly decreased (P < 0.001). The serum SOD level after treatment was higher than that before treatment (P < 0.001). In ASyS-ILD patients, the serum SOD level was significantly negatively correlated with ESR (r = - 0.281, P < 0.001); CRP (r = - 0.262, P < 0.001); CK (r = - 0.3678, P < 0.001); LDH (r = - 0.446, P < 0.001); and ferritin (r = - 0.508, P < 0.001). The serum SOD level in patients with anti-PL-7 antibodies was significantly lower than that in the anti-EJ group (P = 0.039). The serum SOD level in the ASyS-ILD recurrence group was significantly lower than that in the stable group (P = 0.001). The serum SOD level was an independent risk factor for disease recurrence in ASyS-ILD patients (P = 0.037).
conclusionIn patients with ASyS-ILD, low serum SOD levels indicate the presence of oxidative stress. Serum SOD levels decrease in response to increasing inflammation in ASyS-ILD, suggesting that SOD can be used as a valid indicator of disease activity. The serum SOD levels in patients with ASyS-ILD are closely related to recurrence and deserve attention from rheumatologists. Key Points • Our study is the first to explore the relationship between SOD and ASyS-ILD. • This study demonstrates that SOD can serve as a simple and effective biomarker for evaluating the disease activity and recurrence of ASyS-ILD, which provides relevant information for clinical practice and a reliable basis for follow-up studies.
Indexed as
Identifiers
41952032What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.